The study covers the period of 2015-2019, before approvals for CAR T-cell therapy, pirtobrutinib, and the arrival of covalent BTK inhibitors with fewer adverse events in mantle cell lymphoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results